Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
European journal of cancer (Oxford, England : 1990)（2023）
摘要
NCT02646735, https://clinicaltrials.gov/ct2/show/NCT02646735.
更多查看译文
关键词
Exemestane,Fulvestrant,HER2-negative,Oestrogen receptor-positive,Recurrent breast cancer (BC)
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要